Table 1.
Baseline comorbidity characteristics.
| Overall (N = 73) | Lymphoid (N = 29) | Myeloid (N = 44) | |
|---|---|---|---|
| Baseline characteristics | |||
| Age, yrs | 70 ± 10 | 68 ± 12 | 71 ± 9 |
| Female, n (%) | 23 (31.5) | 11 (37.9) | 12 (27.3) |
| Cancer characteristics | |||
| Acute myeloid leukemia, n (%) | 23 (31.5) | – | 23 (52.2) |
| Chronic myelogenous leukemia, n (%) | 19 (26.0) | – | 19 (43.2) |
| Acute lymphoblastic leukemia, n (%) | 1 (1.4) | – | 1 (2.3) |
| Non-Hodgkin’s lymphoma, n (%) | 28 (38.3) | 27 (93.1) | – |
| Other, n (%) | 2 (2.7) | 2 (6.9) | 1 (2.3) |
| Cancer treatment history | |||
| Chemotherapy initiated within 1 month of presentation, n (%) | 22 (30.1) | 9 (31.0) | 13 (29.6) |
| Most common chemotherapies | |||
| Hydroxyurea | 3 (4.1) | 3 (23.1) | |
| Cytarabine | 2 (2.7) | 2 (15.4) | |
| ATRA | 2 (2.7) | 2 (15.4) | |
| Decitabine | 2 (2.7) | 2 (15.4) | |
| Anthracyclines | 16 (21.9) | 9 (100) | 7 (53.9) |
| Vinca alkaloids | 9 (12.3) | 9 (100) | |
| Dexamethasone | 9 (12.3) | 9 (100) | |
| Cyclophosphamide | 8 (11.0) | 8 (88.9) | |
| Rituxamab | 8 (11.0) | 8 (88.9) | |
| Methotrexate | 3 (4.1) | 3 (33.3) | |
| Bleomycin | 2 (2.7) | 2 (22.2) | |
| Ifosfamide | 2 (2.7) | 2 (22.2) | |
| Etoposide | 2 (2.7) | 2 (22.2) | |
| Prior chemotherapy | 28 (38.4) | 20 (69.1) | 8 (18.2)* |
| Prior radiation therapy, n (%) | 5 (6.8) | 5 (17.2) | 0 |
| Prior chest radiation therapy, n (%) | 1 (1.4) | 1 (3.4) | 0 |
| Prior hematopoietic stem cell transplantation, n (%) | 10 (13.7) | 9 (31.0) | 1 (2.3)* |
| Cardiovascular history | |||
| Body mass index, kg/m2 | 27.9 ± 6.3 | 28.2 ± 6.7 | 27.7 ± 6.1 |
| Smoking, n (%) | 50 (68.5) | 19 (65.5) | 31 (70.5) |
| Hypertension, n (%) | 43 (58.9) | 15 (51.7) | 28 (63.6) |
| Hyperlipidemia, n (%) | 36 (49.3) | 14 (48.3) | 22 (50.0) |
| Diabetes, n (%) | 18 (24.7) | 7 (24.1) | 11 (25.0) |
| Chronic kidney disease, n (%) | 12 (16.4) | 4 (13.8) | 8 (18.2) |
| Coronary artery disease, n (%) | 31 (42.5) | 10 (34.5) | 21 (47.7) |
| History of MI | 18 (24.7) | 6 (20.7) | 12 (27.3) |
| History of CABG | 11 (15.1) | 3 (10.3) | 8 (18.2) |
| History of PTCA/PCI | 15 (20.5) | 4 (13.8) | 11 (25.0) |
| Cerebrovascular disease, n (%) | 6 (8.2) | 4 (13.8) | 2 (4.5) |
| Congestive heart failure, n (%) | 6 (8.2) | 2 (6.9) | 4 (9.1) |
| Baseline Ejection fraction, % | 58.0 ± 12.2 | 57.0 ± 12.0 | 58.7 ± 12.5 |
| Baseline medical therapy | |||
| Antiplatelet, n (%) | 27 (37.0) | 12 (41.3) | 15 (34.1) |
| Beta-blocker, n (%) | 40 (54.8) | 14 (48.3) | 26 (59.1) |
| ACEI/ARB, n (%) | 27 (37.0) | 11 (37.9) | 16 (36.4) |
| Statin, n (%) | 27 (37.0) | 10 (34.5) | 17 (38.6) |
| Anticoagulation, n (%) | 7 (9.6) | 5 (17.2) | 2 (4.5) |
| Code status | |||
| DNR | 4 (5.5) | 1 (3.4) | 3 (6.8) |
| DNR/DNI | 10 (13.7) | 5 (17.2) | 5 (11.4) |
| Full code | 52 (71.2) | 21 (72.4) | 31 (70.5) |
| Unknown | 7 (9.6) | 2 (6.9) | 5 (11.4) |
*
p < 0.05 for myeloid vs. lymphoid.